Metsera, which is developing weight-loss drugs, said on Monday it is seeking a valuation of up to $1.78 billion in its U.S.

An analyst thinks he has cracked the code on why highflying Eli Lilly missed two quarters of Wall Street projections.

In recent years, the pharmaceutical industry has undergone significant changes in the focus of its innovation, research and ...

In losing weight, Oprah Winfrey gained a new perspective ... she began using weight loss medications. In fact, Oprah recently detailed the ways in which using the drugs altered the way she ...

Novo Nordisk stock is paring its year-over-year deficit on positive early stage trial results for the company's new weight ...

Novo Nordisk's stock (NVO) rose more than 8% in Friday trading on news that the company's latest weight-loss product delivered favorable results. The new drug, amycretin, similar to the company's ...

Novo Nordisk scored a much-needed win on Friday, with early-stage data on a new weight-loss drug that suggested it could work better than the obesity blockbusters already on the market.

Novo Nordisk (NYSE:NVO) shares are rallying 6.87% to $86.67 as of 10:27 AM ET Friday, after the company reported promising trial results for its new obesity drug ... to 22% weight loss over ...

“I never have used weight loss drugs to ... getting healthy.” New Mom Gypsy-Rose Blanchard Shows Off Postpartum Body ‘Almost a Week’ After Giving Birth GLP-1 drugs — including Ozempic ...

The topline results from the Phase 1b/2a clinical trial showed that patients treated with Amycretin achieved a body weight loss of 9.7% in ... on 20 milligrams of the drug. Meanwhile, patients ...

Novo Nordisk stock jumped Friday after the Danish drugmaker announced new data for a new weight-loss drug which appeared to ...